ArticleFrontiers in genetics2025
Diagnostic and prognostic value of polygene methylation detection in ascites.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore a novel combination of methylation markers for the differential diagnosis of malignant ascites (MA). Materials and methods: A cohort of 164 cancer patients and 20 patients with benign disease presenting with ascites was enrolled. Ascites was tested by means of cytopathological routine diagnosis and DNA methylation detection of SHOX2, RASSF1A, SEPTIN9 and HOXA9 in the cytological specimens. DNA methylation in bisulfite-converted DNA was determined using semi-quantitative methylation-specific real-time PCR (MS-PCR). In addition, Kaplan-Meier method was used to plot the Overall survival (OS) curve based on the methylation status of four genes to explore the relationship between gene methylation status and prognosis of patients with ascites. The Cox regression model was used to analyze the survival factors. Results: Methy-All-In-One Kit (OncoMe), a novel combination of SHOX2, RASSF1A, SEPTIN9 and HOXA9 methylation, led to an additional 29.9% increase in the detection rate of MA combined with the cytopathological test, resulting in a sensitivity of 76.2%. OncoMe showed high positive detection rates in Breast Cancer (87.5%), Pancreatic Cancer (83.3%), Gastric Cancer (79.5%), Cholangiocarcinoma (72.7%) and Ovarian Cancer (68.3%). Patients in the SHOX2 and SEPTIN9 methylation-positive groups had a significantly higher risk of disease progression than those in the negative groups. The OS of SHOX2 and SEPTIN9 gene methylation test negative group was higher than that of positive group. Conclusion: OncoMe has potential for use as a biomarker for the detection of MA. Cytological examination combined with methylation detection can greatly improve the diagnosis rate of malignant ascites. The methylation status of SHOX2 and SEPTIN9 genes is significantly correlated with the prognosis of patients with ascites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.